Strategies to Accelerate Development and De-risk Gene Therapy Manufacturing

Hugh Murray is an upstream scientist for viral vector CDMO in Carlsbad, CA. With more than a decade of industry experience, Hugh has expertise in designing, optimizing, and scaling up mammalian cell culture processes for GMP manufacturing. He is passionate about using statistics and predictive modeling to incorporate data-driven decision-making in his development strategy processes. Hugh has a B.S. in genetics from UC Irvine.

Michael Born is a senior scientist, analytical development for viral vector CDMO in Carlsbad, CA. Michael has been in the biopharma industry for more than 11 years and is accomplished in developing analytical methods, supporting process development, and transferring assays. He is passionate about bringing gene therapies to the rare disease community through testing critical quality attributes and demonstrating product safety and efficacy to regulatory agencies. Michael has a B.S. in bioengineering from SDSU and an M.S. in biotechnology from Northwestern University.

Dayne Callum is a senior scientist, purification process development at our viral vector CDMO in Carlsbad, CA. She has more than 27 years in the biotechnology industry and specializes in the optimization and scale-up of clarification, chromatography, and TFF processes. Dayne has been instrumental in identifying facility fit and equipment constraints to de-risk and streamline technology transfer to manufacturing.